J. Heiligenstein

发表

Atomoxetine Increases Extracellular Levels of Norepinephrine and Dopamine in Prefrontal Cortex of Rat: A Potential Mechanism for Efficacy in Attention Deficit/Hyperactivity Disorder

K. Perry, F. Bymaster, S. Hemrick-Luecke, 2002, Neuropsychopharmacology.

Depression, health-related quality of life, and medical cost outcomes of receiving recommended levels of antidepressant treatment.

W. Katon, K. Chan, D. Revicki, 1998, The Journal of family practice.

Efficacy and safety of atomoxetine in childhood Attention-Deficit/Hyperactivity Disorder with comorbid Oppositional Defiant Disorder

S. West, J. Wernicke, R. Dittmann, 2004, Journal of attention disorders.

Safety of subchronic treatment with fluoxetine for major depressive disorder in children and adolescents.

J. Heiligenstein, E. Brown, M. Joliat, 2004, Journal of child and adolescent psychopharmacology.

Acute Effects of Fluoxetine Versus Placebo on Functional Health and Well-Being in Late-Life Depression

J. Ware, G. Tollefson, K. Beusterien, 1995, International Psychogeriatrics.

A Double-Blind, Placebo-Controlled Clinical Trial of Fluoxetine in Geriatric Patients With Major Depression

G. Tollefson, J. Potvin, J. Heiligenstein, 1995, International Psychogeriatrics.

Tricyclic antidepressant and selective serotonin reuptake inhibitors antidepressant selection and health care costs in the naturalistic setting: a multivariate analysis.

W. Crown, T. Croghan, J. Heiligenstein, 1998, Journal of affective disorders.

AACAP 2002 research forum: placebo and alternatives to placebo in randomized controlled trials in pediatric psychopharmacology.

P. Lavori, G. Clarke, S. Hinshaw, 2004, Journal of the American Academy of Child and Adolescent Psychiatry.

Possible monoamine oxidase inhibitor-serotonin uptake inhibitor interaction: fluoxetine clinical data and preclinical findings.

R. Zerbe, C. Beasley, J. Heiligenstein, 1993, Journal of clinical psychopharmacology.

Is There a Relationship between Baseline and Treatment-Associated Changes in [3H]-IMI Platelet Binding and Clinical Response in Major Depression?

C. Nemeroff, G. Tollefson, D. Knight, 1996, Neuropsychopharmacology.

Treatment of attention-deficit/hyperactivity disorder

J. Heiligenstein, 1993 .

The Double-Blind Variable Placebo Lead-in Period: Results From Two Antidepressant Clinical Trials

G. Tollefson, W. Potter, D. Faries, 2001, Journal of clinical psychopharmacology.

Fluoxetine treatment for obsessive-compulsive disorder in children and adolescents: a placebo-controlled clinical trial.

R. Tamura, D. Geller, J. Heiligenstein, 2001, Journal of the American Academy of Child and Adolescent Psychiatry.

Fluoxetine 40-60 mg versus fluoxetine 20 mg in the treatment of children and adolescents with a less-than-complete response to nine-week treatment with fluoxetine 10-20 mg: a pilot study.

R. Findling, K. Wagner, J. Busner, 2006, Journal of child and adolescent psychopharmacology.

Should anxiety and insomnia influence antidepressant selection: a randomized comparison of fluoxetine and imipramine.

W. Katon, D. Revicki, G. Simon, 1998, The Journal of clinical psychiatry.

Efficacy of atomoxetine versus placebo in school-age girls with attention-deficit/hyperactivity disorder.

J. Biederman, K. Schuh, R. Dittmann, 2002, Pediatrics.

Atomoxetine and methylphenidate treatment in children with ADHD: A prospective, randomized, open-label trial

J. Biederman, J. Wernicke, T. Spencer, 2001, European Neuropsychopharmacology.

Cardiovascular Effects of Atomoxetine in Children, Adolescents, and Adults

J. Wernicke, D. Faries, D. Michelson, 2003, Drug safety.

ATOMOXETINE AND PREGNANCY: Dr. Heiligenstein et al. reply

J. Wernicke, T. Spencer, J. Newcorn, 2003 .

Fluoxetine andsuicide: ameta-analysis ofcontrolled trials of treatment fordepression

C. Beasley, J. Heiligenstein, D. Masica, 1991 .

Fluoxetine treatment for prevention of relapse of depression in children and adolescents: a double-blind, placebo-controlled study.

J. McCracken, R. Findling, K. Wagner, 2004, Journal of the American Academy of Child and Adolescent Psychiatry.

SSRI antidepressant drug use patterns in the naturalistic setting: a multivariate analysis.

W. Crown, T. Croghan, J. Heiligenstein, 1999, Medical care.

Fluoxetine and suicide: a meta-analysis of controlled trials of treatment for depression.

C. Beasley, J. Heiligenstein, D. Murphy, 1991, BMJ.

Fluoxetine Not Associated With Increased Violence or Aggression in Controlled Clinical Trials

E. Coccaro, J. Potvin, C. Beasley, 1992 .

Recovery from depression, work productivity, and health care costs among primary care patients.

W. Katon, D. Revicki, G. Simon, 2000, General hospital psychiatry.

Initial antidepressant choice in primary care. Effectiveness and cost of fluoxetine vs tricyclic antidepressants.

W. Katon, D. Revicki, E. Wagner, 1996, JAMA.

Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder.

J. Biederman, T. Spencer, W. Potter, 2002, The Journal of clinical psychiatry.

A Case Study of an Adaptive Clinical Trial in the Treatment of Out-Patients with Depressive Disorder

Douglas E. Faries, Roy N. Tamura, R. Tamura, 1994 .

Validation of the ADHD Rating Scale as a clirlician administered and scored instrument

D. Faries, J. Heiligenstein, I. Yalcin, 2001 .

A controlled trial of fluoxetine and desipramine in depressed women with advanced cancer

J. Holland, J. Heiligenstein, S. Romano, 1998, Psycho-oncology.

Fluoxetine not associated with increased aggression in controlled clinical trials

J. Potvin, C. Beasley, J. Heiligenstein, 1993, International clinical psychopharmacology.

Fluoxetine for acute treatment of depression in children and adolescents: a placebo-controlled, randomized clinical trial.

K. Wagner, G. Emslie, J. Heiligenstein, 2002, Journal of the American Academy of Child and Adolescent Psychiatry.

The interface between publicly funded and industry-funded research in pediatric psychopharmacology: opportunities for integration and collaboration

L. Greenhill, M. Riddle, J. Fegert, 2004, Biological Psychiatry.

Is Baseline Agitation a Relative Contraindication for a Selective Serotonin Reuptake Inhibitor: A Comparative Trial of Fluoxetine Versus Imipramine

J. Greist, J. Jefferson, G. Tollefson, 1994, Journal of clinical psychopharmacology.

An open-label, dose-ranging study of atomoxetine in children with attention deficit hyperactivity disorder.

S. Faraone, J. Biederman, T. Spencer, 2001, Journal of child and adolescent psychopharmacology.

Changes in Symptoms and Adverse Events After Discontinuation of Atomoxetine in Children and Adults With Attention Deficit/Hyperactivity Disorder: A Prospective, Placebo-Controlled Assessment

S. West, J. Wernicke, T. Spencer, 2004, Journal of clinical psychopharmacology.

Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial.

J. Biederman, J. Wernicke, T. Spencer, 2002, Journal of the American Academy of Child and Adolescent Psychiatry.

Fluoxetine versus tricyclic antidepressants: a prospective multicenter study of antidepressant drug overdoses. The Antidepressant Study Group.

K. Kulig, M. Birkett, J. Brent, 1997, The Journal of emergency medicine.

Initial antidepressant choice in primary care

W. Katon, D. Revicki, E. Wagner, 1996 .

Response patterns of depressed outpatients with and without melancholia: a double-blind, placebo-controlled trial of fluoxetine versus placebo.

G. Tollefson, D. Faries, J. Heiligenstein, 1994, Journal of affective disorders.

A double‐blind trial of fluoxetine, 20 mg, and placebo in out‐patients with DSM‐III-R major depression and melancholia

G. Tollefson, D. Faries, J. Heiligenstein, 1993, International clinical psychopharmacology.

Latency to rapid eye movement sleep as a predictor of treatment response to fluoxetine and placebo in nonpsychotic depressed outpatients

A. Rush, H. Roffwarg, D. Dunner, 1994, Psychiatry Research.

Long-term outcomes of initial antidepressant drug choice in a "real world" randomized trial.

W. Katon, D. Revicki, E. Wagner, 1999, Archives of family medicine.

Safety of atomoxetine in pediatric patients treated for ADHD

J. Wernicke, T. Spencer, D. Dunn, 2001, European Neuropsychopharmacology.

A double-blind, placebo-controlled clinical trial of fluoxetine in geriatric patients with major depression. The Fluoxetine Collaborative Study Group.

G. Tollefson, J. Potvin, J. Heiligenstein, 1995, International psychogeriatrics.

Fluoxetine and suicide : a meta-analysis of controlled trials of treatment for depression

C. Beasley, J. Heiligenstein, D. Murphy, 1992 .

A controlled trial of fluoxetine and desipramine in depressed women with advanced cancer

J. Holland, J. Heiligenstein, S. Romano, 1998, Psycho-oncology.

Acute Medical Costs of Fluoxetine versus Tricyclic Antidepressants

D. Revicki, J. Reblando, K. Kulig, 2012, PharmacoEconomics.